Sponsor: North American Mature Publishers AssociationFaceBook Page | Subscribe Online! | Advertiser Info | Contact Us
         Search Magazine
         Search News
         Search Radio

Heberts Town and Country

  RSS Feeds
MagazineRSS 2.0
NewsRSS 2.0
RadioRSS 2.0
EventsRSS 2.0

Willis-Knighton Seeks Participants for Clinical Trial
August 11th, 2020

Willis-Knighton Seeks Participants for Clinical Trial Investigating Drug to Treat COVID-19

Willis-Knighton Health System is seeking participants to be part of a clinical research study to determine whether a new drug made up of monoclonal antibodies shortens the symptoms of a COVID-19 infection and reduces the need for medical visits or hospitalization due to the virus. Safety will also be assessed. The health system is one of 100 sites in the United States and the only one in the region involved in this study.

“We are proud to have been selected as a clinical research site for this trial, which is being supported by the Federal government,” says Joseph Bocchini, MD, infectious disease specialist at Willis-Knighton. “If proven to reduce the severity of a COVID-19 infection, monoclonal antibodies could become the first recommended outpatient treatment of persons with COVID-19 infection.”

Dr. Bocchini and Clint Wilson, MD, of Family Medical Associates, are principal investigators for the study.

People who qualify to participate must be age 18 or older and have laboratory-confirmed COVID-19 with symptoms such as fever, dry cough, shortness of breath, sore throat, etc. Patients who are currently hospitalized or who have been hospitalized due to COVID-19 are not eligible, says Carrie Kay, RN, CCRC, WK Physician Network clinical research manager.

The duration of the study is 30 days. Participants will receive a single dose of either one of two formulations of the study medication or a placebo at the WK COVID Research Infusion Center and will be monitored at home and tested by healthcare professionals throughout the study.

There is no charge to the participant or insurance for visits, medication, or monitoring. Instead, each patient will receive a small stipend for the time and travel involved for his or her participation.

“We feel this is one of the most promising options as a bridge to keep patients as outpatients until a vaccine is approved,” Kay says.

To learn more about this study and eligibility requirements, call Carrie Kay at (318) 455-9730 or go to https://www.wkhs.com/clinical-trials/ and click on COVID.


  TBT News
>>Medicare and You 2021 Handbook is now available
>>Wish of a Lifetime from AARP
>>Hopeful Alzheimer's and Caregivers' Symposium
>>Willis-Knighton Seeks Participants for Clinical Trial
>>Please thank our advertisers and sponsors
>>Ernest's Orleans brings back Senior Appreciation Discount
>>Attention Grandparents - Bring your grandkids to SciPort Discovery Center
>>Congratulations to the winners of "Scavenger Hunt"
>>Be Aware of New Scans targeting senior citizens
>>The Best of Times magazine wins 15 international awards
>>Caddo Parish Commission honors The Best of Times magazine
>>Apple Podcasts has shows from The Best of Times Radio Hour
>>10 Principles for Staying Vital, Happy, and Sharp
>>Blending the Past with the Present in Shreveport's historical photos
Subscribe Online! | Advertiser Info | Contact Us | Privacy Statement | Confidentiality Policy
©TBT Multimedia, Inc. 2020